{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5","value":"2.6"},{"groupId":"OG001","spread":"26.5","value":"-6.3"},{"groupId":"OG002","spread":"24.7","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"69"}],"units":"Participants"}],"title":"Absenteeism Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.9","value":"-2.1"},{"groupId":"OG001","spread":"28.2","value":"-3.8"},{"groupId":"OG002","spread":"27.2","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"56"}],"units":"Participants"}],"title":"Absenteeism Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"-8"},{"groupId":"OG001","spread":"25","value":"-17"},{"groupId":"OG002","spread":"27","value":"-15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"Presenteeism Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"-17"},{"groupId":"OG001","spread":"23","value":"-20"},{"groupId":"OG002","spread":"21","value":"-17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"title":"Presenteeism Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.7","value":"-4.2"},{"groupId":"OG001","spread":"30.4","value":"-17.6"},{"groupId":"OG002","spread":"23.7","value":"-9.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"Work Productivity Loss Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.1","value":"-15.9"},{"groupId":"OG001","spread":"25.0","value":"-19.6"},{"groupId":"OG002","spread":"23.0","value":"-14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"title":"Work Producivity Loss Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25","value":"-13"},{"groupId":"OG001","spread":"27","value":"-19"},{"groupId":"OG002","spread":"25","value":"-19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"222"},{"groupId":"OG002","value":"213"}],"units":"Participants"}],"title":"Activity Impairment Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"-18"},{"groupId":"OG001","spread":"28","value":"-23"},{"groupId":"OG002","spread":"27","value":"-21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"187"}],"units":"Participants"}],"title":"Activity Impairment Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"229"},{"groupId":"OG002","value":"227"}],"units":"Participants"}],"description":"The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug. Change from baseline includes participants with a baseline value and an observed value at the time point being summarized.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12; Baseline, Week 24","title":"Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores","type":"SECONDARY","unitOfMeasure":"percentage of impairment"}